NeuroRX

, Volume 2, Issue 2, pp 348–360

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease

Article

Summary

The pathophysiologic process leading to neurodegeneration in Alzheimer’s disease (AD) is thought to begin long before clinical symptoms develop. Existing therapeutics for AD improve symptoms, but increasing efforts are being directed toward the development of therapies to impede the pathologic progression of the disease. Although these medications must ultimately demonstrate efficacy in slowing clinical decline, there is a critical need for biomarkers that will indicate whether a candidate disease-modifying therapeutic agent is actually altering the underlying degenerative process. A number ofin vivo neuroimaging techniques, which can reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise as biomarkers. These neuroimaging measures appear to relate closely to neuropathological and clinical data, such as rate of cognitive decline and risk of future decline. As this work has matured, it has become clear that neuroimaging measures may serve a variety of potential roles in clinical trials of candidate neurotherapeutic agents for AD, depending in part on the question of interest and phase of drug development. In this article, we review data related to the range of neuroimaging biomarkers of Alzheimer’s disease and consider potential applications of these techniques to clinical trials, particularly with respect to the monitoring of disease progression in trials of disease-modifying therapies.

Key Words

Alzheimer’s disease mild cognitive impairment magnetic resonance imaging positron emission tomography single-photon emission tomography clinical drug trials biomarkers 

References

  1. 1.
    Kukull WA, Bowen JD. Dementia epidemiology.Med Clin North Am 86: 573–590, 2002.PubMedGoogle Scholar
  2. 2.
    Cummings JL. Alzheimer’s disease.N Engl J Med 351: 56–67, 2004.PubMedGoogle Scholar
  3. 3.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease.Am J Psychiatry 141: 1356–1364, 1984.PubMedGoogle Scholar
  4. 4.
    Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study.Alzheimer Dis Assoc Disord 11(Suppl 2): S22-S32, 1997.PubMedGoogle Scholar
  5. 5.
    Selkoe DJ. Alzheimer’s disease is a synaptic failure.Science 298: 789–791, 2002.PubMedGoogle Scholar
  6. 6.
    Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias.Neurology 63: 1155–1162, 2004.PubMedGoogle Scholar
  7. 7.
    Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse.Nature 400: 173–177, 1999.PubMedGoogle Scholar
  8. 8.
    Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease.Ann Neurol 48: 567–579, 2000.PubMedGoogle Scholar
  9. 9.
    Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.J Neurosci 23: 0879–10883, 2003.Google Scholar
  10. 10.
    DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders.Science 302: 830–834, 2003.PubMedGoogle Scholar
  11. 11.
    Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome.Arch Neurol 56: 303–308, 1999.PubMedGoogle Scholar
  12. 12.
    Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.Arch Neurol 61: 59–66, 2004.PubMedGoogle Scholar
  13. 13.
    Petersen RC. Mild cognitive impairment as a diagnostic entity.J Intern Med 256: 183–194, 2004.PubMedGoogle Scholar
  14. 14.
    Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information.Arch Neurol 57: 675–680, 2000.PubMedGoogle Scholar
  15. 15.
    Fox N, Growdon JH. Biomarkers and surrogates.NeuroRx 1: 181, 2004.Google Scholar
  16. 16.
    Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset alzheimer’s dementia.Proc Natl Acad Sci USA 101: 284–289, 2004.PubMedGoogle Scholar
  17. 17.
    Gomez-Isla T, Rice JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease.J Neurosci 16: 4491–4500, 1996.PubMedGoogle Scholar
  18. 18.
    Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.Ann Neurol 49: 202–213, 2001.PubMedGoogle Scholar
  19. 19.
    Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.Arch Neurol 58: 1395–1402, 2001.PubMedGoogle Scholar
  20. 20.
    Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease.Ann Neurol 44: 288–291, 1998.PubMedGoogle Scholar
  21. 21.
    Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer’s disease.N Engl J Med 343: 450–456, 2000.PubMedGoogle Scholar
  22. 22.
    Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, et al. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia.Neurology 61: 1673–1679, 2003.PubMedGoogle Scholar
  23. 23.
    Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Reclinical prediction of Alzheimer’s disease using SPECT.Neurology 50: 1563–1571, 1998.PubMedGoogle Scholar
  24. 24.
    Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get alzheimer’s disease.Ann Neurol 47: 430–439, 2000.PubMedGoogle Scholar
  25. 25.
    Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial temporal lobe function and structure in mild cognitive impairment.Ann Neurol 56: 27–35, 2004.PubMedGoogle Scholar
  26. 26.
    Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion.Lancet Neurol 1: 13–21, 2002.PubMedGoogle Scholar
  27. 27.
    Bammer R, Skare S, Newbould R, Liu C, Thijs V, Ropele S, Clayton DB, Krueger G, Moseley ME, Glover GH. Foundations of advanced magnetic resonance imaging.NeuroRx 2: 167–196, 2005.PubMedGoogle Scholar
  28. 28.
    Walters RJ, Fox NC, Crum WR, Taube D, Thomas DJ. Haemodialysis and cerebral oedema.Nephron 87: 143–147, 2001.PubMedGoogle Scholar
  29. 29.
    Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics.NeuroRx 2: 277–303, 2005.PubMedGoogle Scholar
  30. 30.
    Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains.Lancet Neurol 2: 79–88, 2003.PubMedGoogle Scholar
  31. 31.
    Ashburner J, Friston KJ. Voxel-based morphometry—the methods.Neuroimage 11: 805–821, 2000.PubMedGoogle Scholar
  32. 32.
    Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains.Neuroimage 14: 21–36, 2001.PubMedGoogle Scholar
  33. 33.
    Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O’Brien JT, Scheltens P, et al. A comprehensive study of gray matter loss in patients with Alzheimer’s disease using optimized voxel-based morphometry.Neuroimage 18: 895–907, 2003.PubMedGoogle Scholar
  34. 34.
    Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, Mega MS, et al. Cortical variability and asymmetry in normal aging and Alzheimer’s disease.Cereb Cortex 8: 492–509, 1998.PubMedGoogle Scholar
  35. 35.
    Csernansky JG, Wang L, Joshi S, Miller JP, Gado M, Kido D, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type.Neurology 55: 1636–1643, 2000.PubMedGoogle Scholar
  36. 36.
    Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, et al. Cortical change in Alzheimer’s disease detected with a disease-specific population-based brain atlas.Cereb Cortex 11: 1–16, 2001.PubMedGoogle Scholar
  37. 37.
    Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.Arch Neurol 57: 339–344, 2000.PubMedGoogle Scholar
  38. 38.
    Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer’s disease pathology.Neurology 61: 487–492, 2003.PubMedGoogle Scholar
  39. 39.
    Mueller EA, Moore MM, Kerr DC, Sexton G, Camicioli RM, Howieson DB, et al. Brain volume preserved in healthy elderly through the eleventh decade.Neurology 51: 1555–1562, 1998.PubMedGoogle Scholar
  40. 40.
    Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain.J Neurosci 23: 3295–3301, 2003.PubMedGoogle Scholar
  41. 41.
    Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, et al. Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer’s disease.Br J Radiol 75: 506–513, 2002.PubMedGoogle Scholar
  42. 42.
    Goncharova II, Dickerson BC, Stoub TR, DeToledo-Morrell L. MRI of human entorhinal cortex: a reliable protocol for volumetric measurement.Neurobiol Aging 22: 737–745, 2001.PubMedGoogle Scholar
  43. 43.
    Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease.Neuroscience 95: 721–725, 2000.PubMedGoogle Scholar
  44. 44.
    Jack CR Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O’Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia.Neurology 58: 750–757, 2002.PubMedGoogle Scholar
  45. 45.
    Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study.Neurology 58: 1476–1482, 2002.PubMedGoogle Scholar
  46. 46.
    De Leon MJ, George AE, Golomb J, Tarshish C, Convit A, Kluger A, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer’s disease.Neurobiol Aging 18: 1–11, 1997.PubMedGoogle Scholar
  47. 47.
    de Toledo-Morrell L, Dickerson B, Sullivan MP, Spanovic C, Wilson R, Bennett DA. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer’s disease.Hippocampus 10: 136–142, 2000.PubMedGoogle Scholar
  48. 48.
    Jack CR Jr, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.Neurology 52: 1397–1403, 1999.PubMedGoogle Scholar
  49. 49.
    Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.J Neurol 246: 477–485, 1999.PubMedGoogle Scholar
  50. 50.
    Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease.Neurobiol Aging 21: 19–26, 2000.PubMedGoogle Scholar
  51. 51.
    Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease.Neurobiol Aging 22: 747–754, 2001.PubMedGoogle Scholar
  52. 52.
    Mungas D, Reed BR, Jagust WJ, DeCarli C, Mack WJ, Kramer JH, et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease.Neurology 59: 867–873, 2002.PubMedGoogle Scholar
  53. 53.
    Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, et al. Assessing the onset of structural change in familial Alzheimer’s disease.Ann Neurol 53: 181–188, 2003.PubMedGoogle Scholar
  54. 54.
    Jack CR Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.Neurology 55: 484–489, 2000.PubMedGoogle Scholar
  55. 55.
    Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study.Biol Psychiatry 47: 557–561, 2000.PubMedGoogle Scholar
  56. 56.
    Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study.Brain 119(Pt 6): 2001–2007, 1996.PubMedGoogle Scholar
  57. 57.
    Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.Neurology 60: 253–260, 2003.PubMedGoogle Scholar
  58. 58.
    Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease.Am J Psychiatry 160: 2003–2011, 2003.PubMedGoogle Scholar
  59. 59.
    DeToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.Neurobiol Aging 25: 1197–1203, 2004.PubMedGoogle Scholar
  60. 60.
    Hsu YY, Schuff N, Du AT, Mark K, Zhu X, Hardin D, et al. Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia.J Magn Reson Imaging 16: 305–310, 2002.PubMedGoogle Scholar
  61. 61.
    Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.Neuron 33: 341–355, 2002.PubMedGoogle Scholar
  62. 62.
    Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex.Cereb Cortex 14: 11–22, 2004.PubMedGoogle Scholar
  63. 63.
    Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias.Neuroimage 17: 29–46, 2002.PubMedGoogle Scholar
  64. 64.
    Testa C, Laakso MP, Sabattoli F, Rossi R, Beltramello A, Soininen H, et al. A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer’s disease.J Magn Reson Imaging 19: 274–282, 2004.PubMedGoogle Scholar
  65. 65.
    Martone ME, Gupta A, Ellisman MH. E-neuroscience: challenges and triumphs in integrating distributed data from molecules to brains.Nat Neurosci 7: 467–472, 2004.PubMedGoogle Scholar
  66. 66.
    Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.NeuroRx 2: 197–214, 2005.PubMedGoogle Scholar
  67. 67.
    Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.Neurology 55: 684–688, 2000.PubMedGoogle Scholar
  68. 68.
    Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O’Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a1H MRS study.Neurology 55: 210–217, 2000.PubMedGoogle Scholar
  69. 69.
    Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, et al.1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer’s disease.J Int Neuropsychol Soc 8: 934–942, 2002.PubMedGoogle Scholar
  70. 70.
    Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer’s disease. A proton MR spectroscopic imaging and MRI study.Neurology 49: 1513–1521, 1997.PubMedGoogle Scholar
  71. 71.
    Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer’s disease.Lancet 355: 1696–1697, 2000.PubMedGoogle Scholar
  72. 72.
    Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients.Neurology 57: 930–932, 2001.PubMedGoogle Scholar
  73. 73.
    Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease.Brain 125: 2332–2341, 2002.PubMedGoogle Scholar
  74. 74.
    Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer’s disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.Am J Psychiatry 154: 1459–1461, 1997.PubMedGoogle Scholar
  75. 75.
    Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.Am J Geriatr Psychiatry 10: 81–88, 2002.PubMedGoogle Scholar
  76. 76.
    Reiman EM, Uecker A, Gonzalez-Lima F, Minear D, Chen K, Callaway NL, et al. Tracking Alzheimer’s disease in transgenic mice using fluorodeoxyglucose autoradiography.Neuroreport 11: 987–991, 2000.PubMedGoogle Scholar
  77. 77.
    Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer’s disease.Brain 122: 1519–1531, 1999.PubMedGoogle Scholar
  78. 78.
    Jagust WJ. Neuroimaging in dementia.Neurol Clin 18: 885–902, 2000.PubMedGoogle Scholar
  79. 79.
    Mega MS, Chu T, Mazziotta JC, Trivedi KH, Thompson PM, Shah A, et al. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer’s disease.Neuroreport 10: 2911–2917, 1999.PubMedGoogle Scholar
  80. 80.
    Mega MS, Chen SS, Thompson PM, Woods RP, Karaca TJ, Tiwari A, et al. Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer’s disease.Neuroimage 5: 147–153, 1997.PubMedGoogle Scholar
  81. 81.
    Bradley KM, O’Sullivan VT, Soper ND, Nagy Z, King EM, Smith AD, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer’s disease.Brain 125: 1772–1781, 2002.PubMedGoogle Scholar
  82. 82.
    Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease.Dement Geriatr Cogn Disord 10: 494–504, 1999.PubMedGoogle Scholar
  83. 83.
    Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, et al. Comparability of FDG PET studies in probable Alzheimer’s disease.J Nucl Med 34: 1460–1466, 1993.PubMedGoogle Scholar
  84. 84.
    Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome.JAMA 286: 2120–2127, 2001.PubMedGoogle Scholar
  85. 85.
    Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type.Neurobiol Aging 13: 93–98, 1992.PubMedGoogle Scholar
  86. 86.
    Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease.Proc Natl Acad Sci USA 97: 6037–6042, 2000.PubMedGoogle Scholar
  87. 87.
    Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease.Neurology 50: 1585–1593, 1998.PubMedGoogle Scholar
  88. 88.
    Brooks DJ. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.NeuroRx 2: 226–236, 2005.PubMedGoogle Scholar
  89. 89.
    Devous MD Sr. Single-photon emission computed tomography in neurotherapeutics.NeuroRx 2: 237–249, 2005.PubMedGoogle Scholar
  90. 90.
    Wolfe N, Reed BR, Eberling JL, Jagust WJ. Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer’s disease.Arch Neurol 52: 257–262, 1995.PubMedGoogle Scholar
  91. 91.
    Jagust WJ, Haan MN, Eberling JL, Wolfe N, Reed BR. Functional imaging predicts cognitive decline in Alzheimer’s disease.J Neuroimaging 6: 156–160, 1996.PubMedGoogle Scholar
  92. 92.
    Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.Neuroreport 12: 851–855, 2001.PubMedGoogle Scholar
  93. 93.
    Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?Neurology 60: 1374–1377, 2003.PubMedGoogle Scholar
  94. 94.
    Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer’s disease.Neurology 38: 909–912, 1988.PubMedGoogle Scholar
  95. 95.
    Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type.Arch Neurol 47: 753–760, 1990.PubMedGoogle Scholar
  96. 96.
    Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies.Am J Psychiatry 159: 738–745, 2002.PubMedGoogle Scholar
  97. 97.
    de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).Proc Natl Acad Sci USA 98: 10966–10971, 2001.PubMedGoogle Scholar
  98. 98.
    Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease.Proc Natl Acad Sci USA 98: 3334–3339, 2001.PubMedGoogle Scholar
  99. 99.
    Mega MS, Cummings JL, O’Connor SM, Dinov ID, Reback E, Felix J, et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.Neuropsychiatry Neuropsychol Behav Neurol 14: 63–68, 2001.PubMedGoogle Scholar
  100. 100.
    Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer’s disease.J Nucl Med 42: 1441–1445, 2001.PubMedGoogle Scholar
  101. 101.
    Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer’s patients during treatment with acetylcholinesterase inhibitors.J Nucl Med 43: 983–990, 2002.PubMedGoogle Scholar
  102. 102.
    Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al. Donepezil HC1 (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study.Am J Geriatr Psychiatry 11: 169–177, 2003.PubMedGoogle Scholar
  103. 103.
    Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease.Ann Neurol 45: 466–472, 1999.PubMedGoogle Scholar
  104. 104.
    Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, Witter MP, Bierlaagh MA, et al. Functional MR imaging in Alzheimer’s disease during memory encoding.AJNR Am J Neuroradiol 21: 1869–1875, 2000.PubMedGoogle Scholar
  105. 105.
    Kato T, Knopman D, Liu H. Dissociation of regional activation in mild AD during visual encoding: a functional MRI study.Neurology 57: 812–816, 2001.PubMedGoogle Scholar
  106. 106.
    Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer’s disease.J Neurol Neurosurg Psychiatry 74: 44–50, 2003.PubMedGoogle Scholar
  107. 107.
    Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O’Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients.Neurology 61: 500–506, 2003.PubMedGoogle Scholar
  108. 108.
    Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model.Nat Neurosci 5: 452–457, 2002.PubMedGoogle Scholar
  109. 109.
    Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease.Neuron 44: 181–193, 2004.PubMedGoogle Scholar
  110. 110.
    Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, et al. Functional MRI detection of pharmacologically induced memory impairment.Proc Natl Acad Sci USA 99: 455–460, 2002.PubMedGoogle Scholar
  111. 111.
    Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease.J Neurol Neurosurg Psychiatry 73: 665–671, 2002.PubMedGoogle Scholar
  112. 112.
    Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.Brain 127: 1574–1583, 2004.PubMedGoogle Scholar
  113. 113.
    Brewer JB, Zhao Z, Desmond JE, Glover GH, Gabrieli JD. Making memories: brain activity that predicts how well visual experience will be remembered.Science 281: 1185–1187, 1998.PubMedGoogle Scholar
  114. 114.
    Wagner AD, Schacter DL, Rotte M, Koutstaal W, Maril A, Dale AM, et al. Building memories: remembering and forgetting of verbal experiences as predicted by brain activity.Science 281: 1188–1191, 1998.PubMedGoogle Scholar
  115. 115.
    Kirchhoff BA, Wagner AD, Maril A, Stern CE. Prefrontal-temporal circuitry for episodic encoding and subsequent memory.J Neurosci 20: 6173–6180, 2000.PubMedGoogle Scholar
  116. 116.
    Daselaar SM, Veltman DJ, Rombouts SA, Raaijmakers JG, Jonker C. Neuroanatomical correlates of episodic encoding and retrieval in young and elderly subjects.Brain 126: 43–56, 2003.PubMedGoogle Scholar
  117. 117.
    Sperling R, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, et al. Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation.Neuroimage 20: 1400–1410, 2003.PubMedGoogle Scholar
  118. 118.
    Rice CJ, Friston KJ. Scanning patients with tasks they can perform.Hum Brain Mapp 8: 102–108, 1999.Google Scholar
  119. 119.
    Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer’s disease.Neurology 46: 692–700, 1996.PubMedGoogle Scholar
  120. 120.
    Stern Y, Moeller JR, Anderson KE, Luber B, Zubin NR, DiMauro AA, et al. Different brain networks mediate task performance in normal aging and AD: defining compensation.Neurology 55: 1291–1297, 2000.PubMedGoogle Scholar
  121. 121.
    Audoin B, Ibarrola D, Ranjeva JP, Confort-Gouny S, Malikova I, Ali-Cherif A, et al. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS.Hum Brain Mapp 20: 51–58, 2003.PubMedGoogle Scholar
  122. 122.
    Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer’s disease.J Neurosci 23: 986–993, 2003.PubMedGoogle Scholar
  123. 123.
    Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease.Am J Geriatr Psychiatry 10: 24–35, 2002.PubMedGoogle Scholar
  124. 124.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B.Ann Neurol 55: 306–319, 2004.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2005

Authors and Affiliations

  • Bradford C. Dickerson
    • 1
    • 2
    • 3
    • 4
  • Reisa A. Sperling
    • 1
    • 2
    • 3
  1. 1.Department of Neurology and the Athinoula A. Martinos Center for Biomedical ImagingMassachusetts General HospitalCharlestown
  2. 2.Memory Disorders Unit, Division of Cognitive and Behavioral Neurology, Department of NeurologyBrigham & Women’s HospitalBoston
  3. 3.Department of NeurologyHarvard Medical SchoolBoston
  4. 4.Gerontology Research UnitMassachusetts General HospitalCharlestown

Personalised recommendations